178 related articles for article (PubMed ID: 28411177)
1. Expression of MRP1 and ABCG2 is associated with adverse clinical outcomes of papillary thyroid carcinoma with a solid component.
Ohashi R; Kawahara K; Namimatsu S; Okamura R; Igarashi T; Sugitani I; Naito Z
Hum Pathol; 2017 Sep; 67():11-17. PubMed ID: 28411177
[TBL] [Abstract][Full Text] [Related]
2. Fine needle aspiration cytology of the papillary thyroid carcinoma with a solid component: A cytological and clinical correlation.
Ohashi R; Murase Y; Matsubara M; Watarai Y; Igarashi T; Sugitani I; Naito Z
Diagn Cytopathol; 2017 May; 45(5):391-398. PubMed ID: 28224716
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological significance of a solid component in papillary thyroid carcinoma.
Ohashi R; Kawahara K; Namimatsu S; Igarashi T; Sakatani T; Sugitani I; Naito Z
Histopathology; 2017 Apr; 70(5):775-781. PubMed ID: 27882585
[TBL] [Abstract][Full Text] [Related]
4. Expression of cancer stem cell markers is more frequent in anaplastic thyroid carcinoma compared to papillary thyroid carcinoma and is related to adverse clinical outcome.
Yun JY; Kim YA; Choe JY; Min H; Lee KS; Jung Y; Oh S; Kim JE
J Clin Pathol; 2014 Feb; 67(2):125-33. PubMed ID: 23986551
[TBL] [Abstract][Full Text] [Related]
5. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
[TBL] [Abstract][Full Text] [Related]
6. Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential.
Lamba Saini M; Weynand B; Rahier J; Mourad M; Hamoir M; Marbaix E
Diagn Pathol; 2015 Apr; 10():32. PubMed ID: 25907675
[TBL] [Abstract][Full Text] [Related]
7. ABCG2/BCRP gene expression is related to epithelial-mesenchymal transition inducer genes in a papillary thyroid carcinoma cell line (TPC-1).
Mato E; González C; Moral A; Pérez JI; Bell O; Lerma E; de Leiva A
J Mol Endocrinol; 2014 Jun; 52(3):289-300. PubMed ID: 24643400
[TBL] [Abstract][Full Text] [Related]
8. Altered expression of estrogen receptor β2 is associated with different biological markers and clinicopathological factors in papillary thyroid cancer.
Dong W; Li J; Zhang H; Huang Y; He L; Wang Z; Shan Z; Teng W
Int J Clin Exp Pathol; 2015; 8(6):7149-56. PubMed ID: 26261608
[TBL] [Abstract][Full Text] [Related]
9. Cytologic, clinicopathologic, and molecular features of papillary thyroid carcinoma with prominent hobnail features: 10 case reports and systematic literature review.
Lee YS; Kim Y; Jeon S; Bae JS; Jung SL; Jung CK
Int J Clin Exp Pathol; 2015; 8(7):7988-97. PubMed ID: 26339365
[TBL] [Abstract][Full Text] [Related]
10. Disparity expression of gammaH2AX in papillary thyroid cancer and nodular goiter.
Hu S; Zhang G; Xu J; Zhu X; Lu X; Jiang L; Wang Q; Hou X; Cao J; Ge M
Clin Lab; 2014; 60(12):2031-7. PubMed ID: 25651738
[TBL] [Abstract][Full Text] [Related]
11. Negative Expression of CPSF2 Predicts a Poorer Clinical Outcome in Patients with Papillary Thyroid Carcinoma.
Sung TY; Kim M; Kim TY; Kim WG; Park Y; Song DE; Park SY; Kwon H; Choi YM; Jang EK; Jeon MJ; Shong YK; Hong SJ; Kim WB
Thyroid; 2015 Sep; 25(9):1020-5. PubMed ID: 26148673
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
Abouhashem NS; Talaat SM
Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma.
Hang D; Dong HC; Ning T; Dong B; Hou DL; Xu WG
Dis Esophagus; 2012; 25(7):638-44. PubMed ID: 22236447
[TBL] [Abstract][Full Text] [Related]
14. Expression of cytokeratin-19 (CK19) in the classical subtype of papillary thyroid carcinoma: the experience of one center in the Silesian region.
Kaliszewski K; Diakowska D; Strutynska-Karpinska M; Rzeszutko M; Grzegrzolka J; Dziegiel P; Wojtczak B; Sutkowski K
Folia Histochem Cytobiol; 2016; 54(4):193-201. PubMed ID: 28051274
[TBL] [Abstract][Full Text] [Related]
15. Encapsulated papillary oncocytic neoplasms of the thyroid: morphologic, immunohistochemical, and molecular analysis of 18 cases.
Woodford RL; Nikiforov YE; Hunt JL; Bellizzi AM; Zhang X; Mills SE; Stelow EB
Am J Surg Pathol; 2010 Nov; 34(11):1582-90. PubMed ID: 20924280
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of G Protein-Coupled Receptor Kinase 6 (GRK6) Is Associated with Progression and Poor Prognosis of Papillary Thyroid Carcinoma.
Che X; Zhang G; Zhang X; Xue J
Med Sci Monit; 2018 May; 24():3540-3548. PubMed ID: 29805156
[TBL] [Abstract][Full Text] [Related]
17. CD1a-positive dendritic cell density predicts disease-free survival in papillary thyroid carcinoma.
Hilly O; Rath-Wolfson L; Koren R; Mizrachi A; Hamzany Y; Bachar G; Shpitzer T
Pathol Res Pract; 2015 Sep; 211(9):652-6. PubMed ID: 26073685
[TBL] [Abstract][Full Text] [Related]
18. Expression of cancer stem cell markers in tall cell variant papillary thyroid cancer identifies a molecular profile predictive of recurrence in classic papillary thyroid cancer.
Beck AC; Rajan A; Landers S; Kelley S; Bellizzi AM; Lal G; Sugg SL; Howe JR; Chan CH; Weigel RJ
Surgery; 2022 Jan; 171(1):245-251. PubMed ID: 34362588
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of putative cancer stem cell markers (CD24, CD44, CD133, and ALDH1) in human papillary thyroid carcinoma.
Han SA; Jang JH; Won KY; Lim SJ; Song JY
Pathol Res Pract; 2017 Aug; 213(8):956-963. PubMed ID: 28687160
[TBL] [Abstract][Full Text] [Related]
20. Treatment Outcomes and Risk Factors for Recurrence After Definitive Surgery of Locally Invasive Well-Differentiated Papillary Thyroid Carcinoma.
Kim JW; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
Thyroid; 2016 Feb; 26(2):262-70. PubMed ID: 26566765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]